Alumis Inc. Common Stock (ALMS)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: fundamentalScore is 2 (below required floor of 3); the strategy requires fundamentalScore >= 3 before any bullish entry. Liquidity and calendar checks passed and the chart improved, but the hard override blocks the trade.
Company overview
Alumis Inc. is a biopharmaceutical company focused on developing therapeutic solutions for autoimmune conditions. Its pipeline includes ESK-001 and A-005, both allosteric TYK2 inhibitors targeting various autoimmune and neuroinflammatory disorders. The company, initially known as Esker Therapeutics, rebranded to Alumis Inc. in 2022 and is headquartered in South San Francisco, California.
Fundamental
weakAlumis is well-funded but remains speculative, with valuation heavily reliant on clinical and regulatory milestones.
Alumis is a clinical-stage biotech with minimal recurring revenue and large R&D-driven losses (FY2025 net loss -$243.33M; trailing free cash flow about -$377.03M). Liquidity is strong: the latest 10-Q reports ~$569.5M of cash/cash equivalents/marketable securities and a current ratio around 7.51, supporting runway into at least the next 12 months (with an 8-K indicating into Q4 2027). Valuation is difficult to justify on current cash flows (EV/Sales ~351x; DCF value roughly $0.47–$1.10/share vs $24.15), while analyst targets (~$39 consensus) reflect pipeline optionality. Overall: well-funded but fundamentally speculative and highly dependent on clinical/regulatory milestones.
Sentiment
fairMedia coverage is light and mixed, with no clear short-term catalysts identified.
No recent company PRs were surfaced via GlobeNewswire, leaving the near-term tape driven mostly by aggregator coverage of sharp price swings (June 1 pullback vs June 12–13 rebound) and a recent Q1 loss update (June 2), both confidence=announced. Last ~14d media tone is mixed-to-slightly-positive but the 30–90d sentiment delta is indeterminate (baseline analyzer returned <3 in-window items after date filtering); legal/regulatory screen is clean.
Technical
goodThe stock shows a strong technical recovery, trading above key averages with improving momentum.
ALMS earns a 4/5 technical score because price exploded above the 20/50/200-day averages and daily VWAP on strong volume, while RSI 61.75, a positive MACD histogram, and ADX 36.48 confirm improving upside momentum. I stop short of a 5 because MACD remains below zero, EMA9 is still below EMA21, and resistance sits just overhead in the 24.86-25.39 zone.
You’re looking at 2026-08-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.